The Competition Commission has reached a landmark agreement with Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceuticals, under which J&J will not enforce its patent on a crucial tuberculosis (TB) drug in 134 low- and middle-income countries. Additionally, J&J will reduce the drug’s price for South Africa’s Department of Health by approximately 40%. This decision not to enforce the…